Warning letter /Mylan / MARCS-CMS 607508
USFDA Warning letter to Mylan in 2020 cited inadequate procedures to monitor and control recovered
Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
